BioSpace News Archive

Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.

Zealand Pharma A/S announced the annual report for the year ended December 31, 2023, and provided a corporate update.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.

AlzeCure Pharma AB announced that its Year-end report for the period January - December 2023 is now available on the company’s website.

Allecra Therapeutics, a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced that the U.S. Food and Drug Administration has approved EXBLIFEP®, as a treatment for complicated urinary tract infections, including pyelonephritis, in patients 18 years and older.

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported financial results for the quarter and year ended December 31, 2023, and provided a business update.

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, provided the following update on the expansion of the clinical trial into Europe.

United Therapeutics Corporation, a public benefit corporation, announced that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.

Tarsus Pharmaceuticals, Inc. announced financial results for the fourth quarter and full-year ended December 31, 2023, and recent business achievements.